Cabaletta Bio (NASDAQ:CABA – Get Rating) posted its quarterly earnings results on Thursday. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.08, MarketWatch Earnings reports.
NASDAQ CABA opened at $1.49 on Friday. The company has a 50 day moving average price of $1.74 and a two-hundred day moving average price of $4.84. Cabaletta Bio has a 12-month low of $1.17 and a 12-month high of $14.95.
Several research analysts recently weighed in on the company. Mizuho dropped their price target on Cabaletta Bio from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, March 18th. Zacks Investment Research lowered Cabaletta Bio from a “buy” rating to a “hold” rating in a research report on Tuesday, February 15th. Finally, HC Wainwright reduced their price target on Cabaletta Bio from $22.00 to $11.00 and set a “buy” rating for the company in a report on Friday, March 18th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $15.88.
About Cabaletta Bio (Get Rating)
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.
- Get a free copy of the StockNews.com research report on Cabaletta Bio (CABA)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.